Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.

Abbrederis, K; Bassermann, F; Schuhmacher, C; Voelter, V; Busch, R; Roethling, N; Sendler, A; Siewert, JR; Peschel, C; Lordick, F

doi:10.1016/j.athoracsur.2006.01.097

2006

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Dokumenttyp:: Journal Article; Article
Autor(en):: Abbrederis, K; Bassermann, F; Schuhmacher, C; Voelter, V; Busch, R; Roethling, N; Sendler, A; Siewert, JR; Peschel, C; Lordick, F
Abstract:: BACKGROUND: In a previous study we showed that many patients with esophagogastric adenocarcinoma experience anemia during neoadjuvant chemotherapy. We now investigated the role of erythropoietin in managing anemia during neoadjuvant chemotherapy. METHODS: Patients with esophagogastric adenocarcinoma who experienced anemia (hemoglobin < 12 g/dL) during neoadjuvant treatment received erythropoietin 10,000 IE subcutaneously three times a week. Primary outcomes were the response to erythropoietin, safety, the need for allogeneic red blood cell transfusion, and the rate of postoperative complications. RESULTS: Between April 2003 and December 2004, 24 patients (median age, 62 years) were enrolled. The mean hemoglobin level before chemotherapy was 12.5 g/dL and the mean hemoglobin level before patients received erythropoietin was 11.5 g/dL. One year after involvement in the trial, 4 of 17 analyzable patients were still anemic (hemoglobin level < 12 mg/dL). Twenty-two patients received erythropoietin, and 16 (73%) responded. We could observe a significant increase in hemoglobin concentrations under therapy with erythropoietin to 12.6 g/dL (p < 0.001). Two patients (8%) received allogeneic transfusions; the rate of postoperative complications was 16%. There were no erythropoietin-related adverse events. CONCLUSIONS: Treatment with erythropoietin is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience anemia during neoadjuvant chemotherapy.
Zeitschriftentitel:: Ann Thorac Surg
Jahr:: 2006
Band / Volume:: 82
Heft / Issue:: 1
Seitenangaben Beitrag:: 293-7
Sprache:: eng
Volltext / DOI:: doi:10.1016/j.athoracsur.2006.01.097
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/16798232
Print-ISSN:: 0003-4975
TUM Einrichtung:: Chirurgische Klinik und Poliklinik; III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Medizinische Statistik und Epidemiologie
BibTeX